NICE has approved rucaparib, a poly‑ADP-ribose polymerase inhibitor, as a maintenance treatment for use in relapsed platinum-sensitive ovarian, fallopian tube, or peritoneal cancer.
Around 1350 people in England may benefit from rucaparib, which can delay the need for further chemotherapy and the associated side-effects.
Rucaparib will be available through the Cancer Drugs Fund (CDF); more evidence is being collected until December 2021. After this, NICE will determine whether or not to recommend that rucaparib be made available on the NHS.
The approval of rucaparib for use through the CDF is conditional on a patient access scheme and commercial access agreement, which makes the drug available at a sufficiently low cost to be considered cost effective.